Avea Pharmaceuticals is trading in short term gains for its new drug, Tracons drug, which is a combination of aripiprazole and aripic acid.

The drug, called Aptensio, has been approved for treating patients with multiple sclerosis and spinal muscular atrophy, and is being used in trials for people with type 1 diabetes.

The stock gained 1.8 percent to $4.40 in premarket trading on Friday.

Shares of Tracon Pharma, which has been developing Tracons own drug for several years, rose 1.4 percent to close at $7.30 in prestock trading.

Aveda Pharma, the largest of the three, is up 3.6 percent to end at $6.94.

Tracons drug is a mixture of arias and phentolamine, which can be used as a pre-treatment drug or for additional treatments when patients are still taking their first drugs.

It was approved for the treatment of type 1 patients in the United States and Europe.